Importantly, high DPAGT1 expression was inversely associated with relapse-free survival (RFS) and overall survival (OS) in patients with HER2+ breast cancer and in patients with HER2+ breast cancer who received trastuzumab treatment (Figure 1, K and L). Here, DPAGT1 is linked to breast cancer.